Related Experiment Video
Updated: Jul 17, 2026
07:14
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
CYP2C8 and antimalaria drug efficacy.
1Karolinska Institute, Malaria Research Unit, Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital, M9:02, KS 17176 Stockholm, Sweden. jose.pedro.gil@ki.se
Pharmacogenomics
|February 9, 2007
Summary
Amodiaquine, a key malaria drug, is metabolized by CYP2C8. This study investigates if CYP2C8 gene variations impact amodiaquine efficacy, potentially affecting millions in Africa.
Area of Science:
- Pharmacogenetics
- Infectious Diseases
- Drug Metabolism
Background:
- Malaria remains a significant global health threat, particularly in Africa, causing millions of deaths.
- Artemisinin-based combination therapies (ACTs) are crucial for malaria treatment, with amodiaquine as a key partner drug.
- Amodiaquine's efficacy relies on its metabolism by the polymorphic cytochrome P450 (CYP) 2C8 enzyme.
Purpose of the Study:
- To review and predict the clinical relevance of CYP2C8 genetic polymorphisms on amodiaquine efficacy.
- To assess the potential impact of these polymorphisms on malaria treatment outcomes.
- To discuss amodiaquine, chloroquine, and dapsone in the context of CYP2C8 variations.
Main Methods:
- Literature review combining in vitro pharmacodynamic and drug metabolism data with in vivo pharmacokinetic information.
- Analysis of existing data on CYP2C8 polymorphism prevalence in African populations.
- Predictive modeling of drug efficacy based on metabolic profiles.
Main Results:
- CYP2C8 genetic variations may influence amodiaquine's therapeutic effect.
- A significant portion of the African population (1-4%) are inferred to be poor metabolizers, potentially impacting drug efficacy.
- Limited in vivo pharmacokinetic data necessitates further research.
Conclusions:
- CYP2C8 polymorphisms may have a role in amodiaquine efficacy, warranting further investigation.
- Understanding these genetic variations is crucial for optimizing malaria treatment strategies.
- The findings have implications for the future use of amodiaquine and other CYP2C8 substrates in malaria-endemic regions.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...